Menu
Search
|

Menu

Close
X

Eyenovia Inc EYEN.OQ (NASDAQ Stock Exchange Capital Market)

2.89 USD
-- (--)
As of Nov 13
chart
Previous Close 2.89
Open --
Volume --
3m Avg Volume 5,219
Today’s High --
Today’s Low --
52 Week High 10.60
52 Week Low 2.70
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.785
FY17
-1.137
FY16
-0.116
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.95
Price to Book (MRQ)
vs sector
--
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
--
17.74
LT Debt to Equity (MRQ)
vs sector
--
13.15
Return on Investment (TTM)
vs sector
--
14.22
Return on Equity (TTM)
vs sector
--
15.99

EXECUTIVE LEADERSHIP

Fredric Eshelman
Chairman of the Board, Since
Salary: --
Bonus: --
Sean Ianchulev
President, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
John Gandolfo
Chief Financial Officer, Since
Salary: --
Bonus: --
Luke Clauson
R & D, Engineering, Since
Salary: --
Bonus: --
Curt Labelle
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

8748 Technology Way
RENO   NV   89521-5925

Phone: +1813.7669539

Eyenovia, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine. MicroProst is its proprietary latanoprost prostaglandin micro-formulation product candidate being developed for a first-line indication therapy for chronic angle closure glaucoma (CACG). MicroStat is a fixed combination micro-formulation product candidate that is being developed for mydriasis (eye dilation). MicroStat is designed to achieve adequate pupil dilation while reducing side-effects associated with conventional mydriatic agents. MicroTears is its micro-droplet ocular surface tear replenishment product candidate. MicroPine is its micro-therapeutic formulation of atropine to target myopia (near sightedness) progression.

SPONSORED STORIES